SERUM TRAIL VE TRAIL RESEPTÖRLERİNİN MEME KANSERİNDEKİ POTANSİYEL ROLÜNÜN ARAŞTIRILMASI

Öz

AMAÇ: Apoptoz, normal hücresel homeostazın sürdürülmesinde kritik bir rol oynar ancak meme kanserinde sıklıkla düzensizlik gösterebilir. Bu çalışma, meme kanseri hastaları ile kontrol grubunda TRAIL, DR4 ve DR5’in serum düzeylerini değerlendirmeyi amaçlamaktadır. Ayrıca, meme kanserinde enflamatuvar ve apoptotik belirteçlerin kapsamlı bir analizini sağlamak için CCL2 ve CCL5’in serum seviyeleri de ölçülecektir. GEREÇ VE YÖNTEM: Bu vaka-kontrol çalışması, Gazi Üniversitesi Tıp Fakültesi Hastanesi genel cerrahi servisinde kayıtlı, yaşları uyumlu 62 meme kanseri hastası ve 62 kontrol grubundan oluşmaktadır. Serum parametreleri prospektif olarak Enzim Bağlantılı İmmünosorbent Test (ELISA) ile ölçülmüştür. BULGULAR: Çalışma, meme kanseri hastalarında kontrol grubuna kıyasla serum DR4 ve DR5 düzeylerinde anlamlı artışlar olduğunu ortaya koymuştur (6,99±1,05'e karşı 4,61±0,61 ng/mL, p=0,003; 1,57±0,12'ye karşı 1,03±0.10 ng/mL, p<0,001, sırasıyla). Serum TRAIL, CCL2 ve CCL5 düzeyleri açısından iki grup arasında anlamlı bir fark gözlenmemiştir. Tümör boyutu 2 cm’den büyük olan hastalarda serum CCL2 düzeyi anlamlı derecede daha yüksekti (p=0,007). Ayrıca, hasta grubunda TRAIL ile DR5/CCL5 serum konsantrasyonları arasında pozitif bir korelasyon bulunmuştur. SONUÇ: Meme kanseri hastalarında serum DR4 ve DR5 düzeylerinin yüksek bulunması, bu biyobelirteçlerin tanısal amaçla kullanılabileceğini düşündürmektedir. Ayrıca, TRAIL ile DR5 ve CCL5 arasındaki pozitif korelasyon, apoptoz ve bağışıklık yanıtı arasındaki olası bir etkileşimi göstermektedir. Bu ilişkilerin daha net anlaşılması için ileri çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

• TNF'ye bağlı apoptoz indükleyici ligand (TRAIL)
• Ölüm reseptörü 4 (DR4)
• Ölüm reseptörü 5 (DR5)
• Meme kanseri.

INVESTIGATION OF THE POTENTIAL ROLE OF SERUM TRAIL AND TRAIL RECEPTORS IN BREAST CANCER

Öz

OBJECTIVE: Apoptosis is crucial for maintaining normal cellular homeostasis, but dysregulation may frequently be observed in breast cancer. This study aims to evaluate the serum levels of TRAIL, DR4, and DR5 in patients with breast cancer and the control group. Additionally, the serum levels of CCL2 and CCL5 will also be measured to provide a comprehensive analysis of inflammatory and apoptotic markers in breast cancer. MATERIAL AND METHODS: This case-control study consists of 62 breast cancer patients and 62 age-matched controls, enrolled in general surgery service at the Gazi University Medical Faculty Hospital. Serum parameters were measured prospectively via Enzyme-Linked Immunosorbent Assay. RESULTS: Serum levels of DR4 and DR5 were significantly higher in breast cancer patients compared to the controls (6.99±1.05 versus 4.61±0.61 ng/mL, p=0.003; 1.57±0.12 versus 1.03±0.10 ng/mL, p<0.001, respectively). No statistically significant differences were observed between the two groups in TRAIL, CCL2 or CCL5 levels. However, serum CCL2 levels were significantly elevated in patients with a tumour size greater than 2 cm (p=0.007). Moreover, a positive correlation was found between the serum concentrations of TRAIL and DR5/CCL5 in the patient group. CONCLUSIONS: Elevated serum levels of DR4 and DR5 in breast cancer patients suggest their potential as diagnostic biomarkers. Additionally, the observed positive correlation between TRAIL and DR5, and CCL5 may reflect a complex interplay between apoptosis and immune response. Further studies are needed to better understand these relationships.

Anahtar Kelimeler

• TNF-related apoptosis-inducing ligand (TRAIL)
• Death receptor 4 (DR4)
• Death receptor 5 (DR5)
• Breast cancer

Kaynakça

1. 1. Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20(3):175-93.
2. 2. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10(1):66-75.
3. 3. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516.
4. 4. Wan Z, Zhang X, Yu X, Hou Y. Prognostic significance of serum soluble DR5 levels in small-cell lung cancer. Int J Med Sci. 2019;16(3):403-8.
5. 5. Mielczarek-Palacz A, Sikora J, Kondera-Anasz Z. Assessment of concentrations of sTRAIL ligand and its receptors sTRAIL-R1 and sTRAIL-R2 - markers monitoring the course of the extrinsic pathway of apoptosis induction: potential application in ovarian cancer diagnostics. Arch Med Sci. 2017;13(3):624-8.
6. 6. Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 Axis in Cancer Progression. Cancers (Basel). 2020;12(7):1765.
7. 7. Tang W, Wang W, Zhang Y, et al. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B. FEBS J. 2009;276(2):581-93.
8. 8. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008;267(2):271-85.

9. 9. Le Cornet C, Jung AY, Johnson TS, et al. Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort. Breast Cancer Res. 2023;25(1):42.
10. 10. Celik B, Didem Yalcin A, Esra Genc G, Gumuslu S. Proteomics pattern of peritoneal sApo-2L but not CD200 (OX-2) as a possible screening biomarker for metastatic ovarian, endometrial and breast carcinoma. J buon. 2015;20(1):280-6.
11. 11. Papila KB, Sozer V, Cigdem KP, et al. Circulating nuclear factor-kappa B mediates cancer-associated inflammation in human breast and colon cancer. J Med Biochem. 2021;40(2):150-9.
12. 12. Yildiz R, Benekli M, Buyukberber S, et al. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer. J Cancer Res Clin Oncol. 2010;136(10):1471-6.
13. 13. Yu X, Du J, Zhai C, et al. Clinical significance of serum soluble death receptor 5 concentration in locally advanced non-small cell lung cancer patients. Oncol Lett. 2014;8(3):1333-9.
14. 14. Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2(12):1125-31.
15. 15. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50-6.
16. 16. Autenshlyus AI, Arkhipov SA, Kunts TA, et al. Cytokine profiles of tumor supernatants in invasive ductal cancer and fibroadenoma of the breast and its relationship with VEGF-A expression in the tumors. Int J Immunopathol Pharmacol. 2017;30(1):83-8.
17. 17. Lebrecht A, Grimm C, Lantzsch T, et al. Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol. 2004;25(1-2):14-7.
18. 18. Lubowicka E, Przylipiak A, Zajkowska M, et al. Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients. Biomed Res Int. 2018;2018:2124390.
19. 19. Fujimoto Y, Inoue N, Morimoto K, et al. Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer. Cancer Sci. 2020;111(1):209-18.
20. 20. Smeets A, Brouwers B, Hatse S, et al. Circulating CCL5 Levels in Patients with Breast Cancer: Is There a Correlation with Lymph Node Metastasis? ISRN Immunology. 2013;2013:1-5.
21. 21. Levina V, Marrangoni AM, DeMarco R, et al. Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production. Exp Cell Res. 2008;314(7):1605-16.
22. 22. Khalis M, Charbotel B, Chajès V, et al. Menstrual and reproductive factors and risk of breast cancer: A case- control study in the Fez region, Morocco. PLoS One. 2018;13(1):e0191333.
23. 23. Harris AR, Wang T, Heng YJ, et al. Association of early menarche with breast tumor molecular features and recurrence. Breast Cancer Research. 2024;26(1):102.
24. 24. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539-52.